TrialBlood advances2025

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Andrew J Yee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.